From: Treatment persistence of biologics among patients with psoriatic arthritis
 | HR | 95.0% CI | |
---|---|---|---|
Lower | Upper | ||
Female vs. male | 1.249 | 1.134 | 1.376 |
Age 30–39 (compared to 18–29) | 0.972 | 0.785 | 1.204 |
Age 40–49 | 1.000 | 0.810 | 1.234 |
Age 50–59 | 1.032 | 0.836 | 1.273 |
Age 60–69 | 0.945 | 0.758 | 1.178 |
Age > 70 | 1.061 | 0.812 | 1.387 |
SES—medium | 0.898 | 0.798 | 1.011 |
SES—high | 0.918 | 0.805 | 1.048 |
Ethnicity—Arab | 1.136 | 0.972 | 1.328 |
Ethnicity—Jewish | 0.913 | 0.693 | 1.203 |
Charlson comorbidity index | 1.004 | 0.973 | 1.035 |
BMI_thin | 1.146 | 0.833 | 1.577 |
BMI_overweight | 1.082 | 0.952 | 1.228 |
BMI_obese | 1.126 | 0.993 | 1.278 |
Smokers | 1.109 | 1.008 | 1.219 |
Concomitant MTX | 0.830 | 0.737 | 0.933 |
Concomitant cDMARDs | 0.958 | 0.811 | 1.131 |
MTX use before | 0.891 | 0.788 | 1.008 |
cDMARDs use before | 1.027 | 0.931 | 1.134 |
Concurrent GC | 0.569 | 0.515 | 0.629 |
Rx line2 vs. line1 | 1.263 | 1.117 | 1.427 |
Rx line3 vs. line1 | 1.296 | 1.119 | 1.500 |
Rx line4 vs. line1 | 1.590 | 1.382 | 1.829 |
Start of biologic 2012 vs. 2018 | 1.657 | 1.339 | 2.051 |
Start of biologic 2013 vs. 2018 | 1.526 | 1.234 | 1.887 |
Start of biologic 2014 vs. 2018 | 1.484 | 1.204 | 1.829 |
Start of biologic 2015 vs. 2018 | 1.521 | 1.233 | 1.878 |
Start of biologic 2016 vs. 2018 | 1.697 | 1.393 | 2.066 |
Start of biologic 2017 vs.2018 | 1.410 | 1.157 | 1.719 |